Great Chemistry Cures
At Enanta, we are committed to creating important, novel medicines by pursuing bold ideas, employing rigorous research, and striving for scientific excellence in everything we do. We are fortunate to have some of the best and brightest minds across pharma and biotech working at Enanta. We are passionate about science and dedicated to discovering and developing highly differentiated therapeutics through innovative chemistry to treat diseases in areas of high unmet need. These efforts have resulted in developing drugs for combination regimens that have cured hundreds of thousands of people with chronic hepatitis C virus infection. It’s incredibly rewarding for our scientific expertise to have such an impact on patients’ lives, and this drives us to do it again in other disease areas.
Enanta’s heritage is steeped in scientific expertise and a track record of effective innovation. Without either, we wouldn’t be where we are today. We are dedicated to applying these capabilities and experience each day in hopes of improving patients’ lives. We’ve done it before, and we’re determined to do it again.
March 8, 2022
Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
February 17, 2022
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
February, 16 2022
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
August 8, 2022
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
August 8, 2022
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
August 1, 2022
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022